Literature DB >> 27372739

Transradial versus transfemoral access for female patients who underwent primary PCI in STEMI: Two years follow-up data from acute STEMI interventional registry.

Sasko Kedev1, Renan Sukmawan2, Oliver Kalpak3, Surya Dharma2, Slobodan Antov3, Jorgo Kostov3, Hristo Pejkov3, Igor Spiroski3.   

Abstract

BACKGROUND: Female patients possess a higher risk for poorer outcome in ST segment elevation myocardial infarction (STEMI). There is possibility that transradial access (TRA) for primary percutaneous coronary intervention (PPCI) could provide better outcome than transfemoral access (TFA) in female patients with STEMI.
METHODS: From 2008 to 2010, 418 female patients (out of 1808 patients) underwent PPCI for acute STEMI. The registry recruited all-comers patients with acute STEMI. Cardiac mortality, major bleeding, and overall MACE rates (composite of death, stroke, re MI and target vessel revascularization-TVR) after 2years follow-up were compared between TRA and TFA.
RESULTS: TRA for PPCI was performed in 261 patients and 157 underwent TFA PPCI. The 30-days, 1year mortality and 2year mortality rates were lower in TRA compared to TFA (6.9% vs.14.6%, p=0.012, 8.8% vs. 15.3%, p=0.045, and 9.2% vs. 16.6%, p=0.027respectively). After 2years follow-up, the overall MACE rates were similar (26.4% vs. 31.2%, p=0.336). The overall major bleeding and major vascular access site bleeding were more favorable for TRA than TFA (4.4 vs. 14%, p<0.001, and 2.7 vs. 10.8%, p<0.001, respectively).
CONCLUSION: Transradial access for primary PCI in female patients provided better clinical outcomes with lower cardiac mortality and reduced major bleeding in comparison to TFA. There was no significant difference at 2years MACE between TRA and TFA.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Outcomes; ST-segment elevation myocardial infarction, primary PCI; Transradial access; Women

Mesh:

Year:  2016        PMID: 27372739     DOI: 10.1016/j.ijcard.2016.06.222

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.

Authors:  Minke H T Hartman; Jake K B Prins; Remco A J Schurer; Erik Lipsic; Chris P H Lexis; Anouk N A van der Horst-Schrivers; Dirk J van Veldhuisen; Iwan C C van der Horst; Pim van der Harst
Journal:  Clin Res Cardiol       Date:  2017-07-28       Impact factor: 5.460

2.  Both baseline Selvester QRS score and change in QRS score predict prognosis in patients with acute ST-segment elevation myocardial infarction after percutaneous coronary intervention.

Authors:  Qian Liu; Yong Zhang; Pengqiang Zhang; Junbo Zhang; Xiaojiao Cao; Shanshan He; Donghui Yang
Journal:  Coron Artery Dis       Date:  2020-08       Impact factor: 1.717

3.  Value of ATRIA risk score and gender in predicting adverse events in patients with myocardial infarction.

Authors:  Can Ramazan Öncel
Journal:  Anatol J Cardiol       Date:  2018-12       Impact factor: 1.596

4.  Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention.

Authors:  Arvindra Krishnamurthy; Claire Keeble; Michelle Anderson; Kathryn Somers; Natalie Burton-Wood; Charlotte Harland; Paul Baxter; Jim McLenachan; Jonathan Blaxill; Daniel J Blackman; Christopher Malkin; Stephen Wheatcroft; John Greenwood
Journal:  Open Heart       Date:  2019-06-29

5.  A Comparison of Transradial and Transfemoral Percutaneous Coronary Intervention in Chinese Women Based on a Propensity Score Analysis.

Authors:  Yi Xu; Chen Jin; Shubin Qiao; Yongjian Wu; Hongbing Yan; Kefei Dou; Bo Xu; Jingang Yang; Yuejin Yang
Journal:  Korean Circ J       Date:  2018-08       Impact factor: 3.243

6.  Transradial Versus Transfemoral Approach for Coronary Angiography in Females with Prior Bypass Surgery.

Authors:  Ahmed Amro; Kanaan Mansoor; Mohammad Amro; Hisham Hirzallah; Amal Sobeih; Damir Kusmic; Ziad Abuhelwa; Majd Kanbour; Adee Elhamdani; Obadah Aqtash; Mehiar Elhamdani
Journal:  Cureus       Date:  2020-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.